DESONIDE PIVALATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C29H40O7
Molecular Weight	500.6237
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COC(=O)C(C)(C)C

InChI

InChIKey=FAPMGCFSVXGXMO-FHKBAQRKSA-N

InChI=1S/C29H40O7/c1-25(2,3)24(33)34-15-21(32)29-22(35-26(4,5)36-29)13-19-18-9-8-16-12-17(30)10-11-27(16,6)23(18)20(31)14-28(19,29)7/h10-12,18-20,22-23,31H,8-9,13-15H2,1-7H3/t18-,19-,20-,22+,23+,27-,28-,29+/m0/s1

HIDE SMILES / InChI

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db13f47-aaab-4054-8b0d-0e23d44dc848

Desonide is a topical glucocorticoid which was approved by FDA for the treatment of such conditions as eczema, psoriasis, atopic dermatitis, etc. The exact mechanism of drug action is unknown.

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Atopic dermatitis 43 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db13f47-aaab-4054-8b0d-0e23d44dc848	Primary	Approved 8429	DESONIDE Approved Use Desonide Ointment, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. It should not be used for longer than two weeks unless directed by a physician. Launch Date 1972
Eczema 46 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db13f47-aaab-4054-8b0d-0e23d44dc848	Primary	Approved 8429	DESONIDE Approved Use Desonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Launch Date 1972
Seborrheic dermatitis 15 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db13f47-aaab-4054-8b0d-0e23d44dc848	Primary	Approved 8429	DESONIDE Approved Use Desonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Launch Date 1972
Contact dermatitis 20 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db13f47-aaab-4054-8b0d-0e23d44dc848	Primary	Approved 8429	DESONIDE Approved Use Desonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Launch Date 1972
Psoriasis 84 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db13f47-aaab-4054-8b0d-0e23d44dc848	Primary	Approved 8429	DESONIDE Approved Use Desonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Launch Date 1972

Doses

Dose	Population	Adverse events
0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.3	unhealthy n = 425 Health Status: unhealthy Condition: Atopic dermatitis Population Size: 425 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.3	Disc. AE: Telangiectasia... AEs leading to discontinuation/dose reduction: Telangiectasia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.3
0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1	Disc. AE: Cushing's syndrome, Hypothalamic pituitary adrenal axis suppression... AEs leading to discontinuation/dose reduction: Cushing's syndrome Hypothalamic pituitary adrenal axis suppression Atrophy Striae Irritation skin Acneiform eruption Skin hypopigmentation Allergic contact dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1

AEs

AE	Significance	Dose	Population
Telangiectasia	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.3	unhealthy n = 425 Health Status: unhealthy Condition: Atopic dermatitis Population Size: 425 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.3
Acneiform eruption	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1
Allergic contact dermatitis	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1
Atrophy	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1
Cushing's syndrome	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1
Hypothalamic pituitary adrenal axis suppression	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1
Irritation skin	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1
Skin hypopigmentation	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1
Striae	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21324lbl.pdf#page=4 Page: 4,8	yes		yes (co-administration study) Comment: Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide. If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21324lbl.pdf#page=4 Page: 4,8

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:204734	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:204734
ChemicalBook	CB2783466	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2783466
MolPort	MolPort-003-987-087	https://www.molport.com/shop/molecule-link/MolPort-003-987-087
Selleck Chemicals	Desonide	http://www.selleckchem.com/products/Desonide.html
ZINC	ZINC000004212851	http://zinc15.docking.org/substances/ZINC000004212851
eMolecules	31225502	https://www.emolecules.com/cgi-bin/more?vid=31225502
eMolecules	6842825	https://www.emolecules.com/cgi-bin/more?vid=6842825

PubMed

Title	Date	PubMed
Allergic contact dermatitis from topical corticosteroids.	1989 Aug	2530056
A double-blind placebo-controlled study of ketoconazole + desonide gel combination in the treatment of facial seborrheic dermatitis.	2002	12077544
[Connubial contact dermatitis to an inhaled corticosteroid].	2005 Feb	15798566
Erythematous scaling eyelids: patient history, exposure to allergens and irritants are keys to diagnosis.	2005 Jun	16001768
Corneofungimetry bioassay on Malassezia spp. under ketoconazole and desonide influences.	2005 Mar-Apr	15767771
Tega-dermabrasion.	2007 Sep	17721261
Desonide foam 0.05%: safety in children as young as 3 months.	2008 Aug	18638631
Nephrotic state as a risk factor for developing posterior reversible encephalopathy syndrome in paediatric patients with nephrotic syndrome.	2008 Aug	18258739
New and emerging trends in the treatment of atopic dermatitis.	2008 Feb 2	19920986
A simple and rapid ESI-LC-MS/MS method for simultaneous screening of doping agents in urine samples.	2009 Apr	20336223
Rhabdomyomatous mesenchymal hamartoma: clinical overview and report of a case with spontaneous regression.	2009 Dec	20583694
Treatment of scalp and facial seborrheic dermatitis with desonide hydrogel 0.05%.	2009 Feb	20967179
Vitiligo after diphencyprone for alopecia areata.	2010	20585597
Generic sample preparation combined with high-resolution liquid chromatography-time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories.	2010 Apr	20155493
Pediatric atopic dermatitis: a review of the medical management.	2010 Sep	20628042

Patents

Sample Use Guides

In Vivo Use Guide

Desonide Cream, 0.05% should be applied to the affected area as a thin film two to four times daily depending on the severity of the condition.

Route of Administration: Topical

In Vitro Use Guide

Unknown

Name

Type

Language

DESONIDE PIVALATE

Common Name

English

PREGNA-1,4-DIENE-3,20-DIONE, 21-(2,2-DIMETHYL-1-OXOPROPOXY)-11-HYDROXY-16,17-((1-METHYLETHYLIDENE)BIS(OXY))-, (11.BETA.,16.ALPHA.)-

Systematic Name

English

Desonide pivalate [WHO-DD]

Common Name

English

Code System Code Type Description

SMS_ID

300000034982